ArticleJournal of Indian Association of Pediatric Surgeons
Predictors for Recurrence in Hepatoblastoma: Single-center Study.
Article in Journal of Indian Association of Pediatric Surgeons. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatoblastoma is the most common primary liver malignancy in children, and advances in multimodal therapy have significantly improved survival outcomes. Despite the improvements, tumor recurrence remains a major clinical challenge and continues to adversely affect long-term survival. Materials and Methods: This is a retrospective study of all children who underwent hepatic resection for hepatoblastoma from January 2015 to June 2024. All children had alpha-fetoprotein (AFP) and contrast-enhanced computed tomography (CECT) chest, abdomen, and pelvis at the time of diagnosis. All children underwent neoadjuvant chemotherapy as per SIOPEL protocol followed by hepatic resections. Depending on the CECT findings, postchemotherapy either hepatectomy (right/left/central) or liver transplantation was performed. Postsurgery chemotherapy schedule was completed. Children were followed up after 3 months and subsequently at 6 monthly intervals for 3 years. On follow-up AFP and USG were done, and in cases of elevated AFP levels or doubtful lesion on USG, CECT chest, abdomen, and pelvis were done. Eight potential risk factors - age, AFP level, PRETEXT stage, histology, surgical approach, vascular involvement, surgical margin status, and SIOPEL high-risk category - were evaluated for their association with tumor recurrence using Fisher's exact test. Data were analyzed. Results: Twenty-five children were included in the study, of which 14 were boys and 11 were girls. The mean age at the time of surgery was 27 months. The mean follow-up period was 38 months. Eleven children underwent hepatectomy (right/left/central) while 4 underwent liver transplantation. Tumor recurrence was observed in five patients (20%), with all cases presenting as distant metastases involving the lungs or mediastinal lymph nodes. Vascular (either portal or hepatic vein) involvement ( Conclusion: Vascular involvement and liver transplantation emerged as the key predictors of hepatoblastoma recurrence. The factors such as age, AFP level, PRETEXT stag, histopathology, tumor margin positivity, and high risk as per the SIOPEL guidelines were not associated with tumor recurrence. Recurrence was predominantly distant and associated with increased mortality. Larger multicenter studies are needed to validate these findings and to further refine risk-stratified management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.